In addition, one case achieved a near CR within 18 months and found that the anti-oncogene TSC2 in this patient’s pretreated tumor tissue contained a somatic nonsense mutation that reactivated the mTOR pathway, which may reveal a mechanism of drug resistance [91]. This evidence concerns the gene TSC2 and neoplasm.